57976-99-5

Basic information

• Product Name: Benzoyl chloride, 4-fluoro-2-hydroxy- (9CI)
• Synonyms: Benzoyl chloride, 4-fluoro-2-hydroxy- (9CI);2-Hydroxy-4-fluorobenzoyl chloride
• CAS NO: 57976-99-5
• Molecular Formula: C₇H₄ClFO₂
• Molecular Weight: 174.5568632
• Product Categories: ACIDHALIDE
• Mol File: 57976-99-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoyl chloride, 4-fluoro-2-hydroxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-fluoro-2-hydroxy- (9CI)(57976-99-5)
• EPA Substance Registry System: Benzoyl chloride, 4-fluoro-2-hydroxy- (9CI)(57976-99-5)

Safety Data

• Hazardous Substances Data: 57976-99-5(Hazardous Substances Data)

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 

Downstream Products

• 314298-36-7 N-cyanomethyl-4-fluoro-2-hydroxy-benzamide 
• 314298-05-0 4-fluoro-2-hydroxy-N-(3-nitrobenzyl)-benzamide 
• 314298-06-1 [5-fluoro-2-(3-nitro-benzylcarbamoyl)-phenoxy]-acetic acid ethyl ester 
• 314298-07-2 [5-fluoro-2-(3-nitro-benzylthiocarbamoyl)-phenoxy]-acetic acid ethyl ester 
• 314298-37-8 4-fluoro-2-hydroxy-N-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-benzamide 
• 915771-25-4 4-fluoro-2-hydroxy-N-methyl-benzamide 

Relevant articles and documents

SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway

Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.

Intramolecular metal-free oxidative aryl-aryl coupling: An unusual hypervalent-iodine-mediated rearrangement of 2-substituted n-phenylbenzamides

Hypervalent-iodine-mediated oxidative coupling of the two aryl groups in either 2-acylamino-N-phenyl-benzamides or 2-hydroxy-N-phenylbenzamides, with concomitant insertion of the ortho-substituted N or O atom into the tether, has been described for the first time. This unusual metal-free rearrangement reaction involves an oxidative C(sp2)?C(sp2) aryl-aryl bond formation, cleavage of a C(sp2)?C(O) bond, and a lactamization/lactonization. Furthermore, unsymmetrical diaryl compounds can be easily obtained by removing the tether within the cyclized product.

HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.